Literature DB >> 21898354

Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and results.

D H Solomon1, E Mercer, A Kavanaugh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 21898354      PMCID： PMC3241884          DOI： 10.1002/art.30653

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  40 in total

1.  Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis.

Authors:  Soko Setoguchi; Daniel H Solomon; Michael E Weinblatt; Jeffrey N Katz; Jerry Avorn; Robert J Glynn; E Francis Cook; Greg Carney; Sebastian Schneeweiss
Journal:  Arthritis Rheum       Date:  2006-09

2.  Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly.

Authors:  Til Stürmer; Sebastian Schneeweiss; M Alan Brookhart; Kenneth J Rothman; Jerry Avorn; Robert J Glynn
Journal:  Am J Epidemiol       Date:  2005-05-01       Impact factor: 4.897

Review 3.  EBV the prototypical human tumor virus--just how bad is it?

Authors:  David A Thorley-Lawson
Journal:  J Allergy Clin Immunol       Date:  2005-08       Impact factor: 10.793

4.  Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.

Authors:  J Askling; C M Fored; E Baecklund; L Brandt; C Backlin; A Ekbom; C Sundström; L Bertilsson; L Cöster; P Geborek; L T Jacobsson; S Lindblad; J Lysholm; S Rantapää-Dahlqvist; T Saxne; L Klareskog; N Feltelius
Journal:  Ann Rheum Dis       Date:  2005-04-20       Impact factor: 19.103

5.  Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists.

Authors:  J Askling; C M Fored; L Brandt; E Baecklund; L Bertilsson; N Feltelius; L Cöster; P Geborek; L T Jacobsson; S Lindblad; J Lysholm; S Rantapää-Dahlqvist; T Saxne; L Klareskog
Journal:  Ann Rheum Dis       Date:  2005-04-13       Impact factor: 19.103

Review 6.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

Authors:  Tim Bongartz; Alex J Sutton; Michael J Sweeting; Iain Buchan; Eric L Matteson; Victor Montori
Journal:  JAMA       Date:  2006-05-17       Impact factor: 56.272

7.  Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors.

Authors:  Eliza F Chakravarty; Kaleb Michaud; Frederick Wolfe
Journal:  J Rheumatol       Date:  2005-11       Impact factor: 4.666

Review 8.  Tumor necrosis factor-alpha in the pathogenesis and treatment of cancer.

Authors:  G Mark Anderson; Marian T Nakada; Mark DeWitte
Journal:  Curr Opin Pharmacol       Date:  2004-08       Impact factor: 5.547

9.  Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta-analysis by Bongartz et al.

Authors:  Will Dixon; Alan Silman
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

Review 10.  Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritis.

Authors:  J Franklin; M Lunt; D Bunn; D Symmons; A Silman
Journal:  Ann Rheum Dis       Date:  2005-10-25       Impact factor: 19.103
View more
  15 in total

1.  Updated recommendations for the treatment of rheumatoid arthritis: another step on a long road.

Authors:  David I Daikh; E William St Clair
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-05       Impact factor: 4.794

2.  Rheumatoid arthritis - an update for general dental practitioners.

Authors:  S de Souza; R K Bansal; J Galloway
Journal:  Br Dent J       Date:  2016-11-18       Impact factor: 1.626

3.  Creating a tumor-resistant microenvironment: cell-mediated delivery of TNFα completely prevents breast cancer tumor formation in vivo.

Authors:  Mazhar Al-Zoubi; Ahmed F Salem; Ubaldo E Martinez-Outschoorn; Diana Whitaker-Menezes; Rebecca Lamb; James Hulit; Anthony Howell; Ricardo Gandara; Marina Sartini; Hwyda Arafat; Generoso Bevilacqua; Federica Sotgia; Michael P Lisanti
Journal:  Cell Cycle       Date:  2012-02-01       Impact factor: 4.534

4.  Risk of malignancy in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under immunosuppressive therapy: a single-center experience.

Authors:  Marta Fantò; Mario Stefano Peragallo; Mario Pietrosanti; Roberta Di Rosa; Andrea Picchianti Diamanti; Simonetta Salemi; Raffaele D'Amelio
Journal:  Intern Emerg Med       Date:  2015-06-23       Impact factor: 3.397

5.  In vivo maturation of allo-specific CD8 CTL and prevention of lupus-like graft-versus-host disease is critically dependent on T cell signaling through the TNF p75 receptor but not the TNF p55 receptor.

Authors:  Kateryna Soloviova; Maksym Puliaiev; Mark Haas; Charles S Via
Journal:  J Immunol       Date:  2013-03-22       Impact factor: 5.422

Review 6.  Malignancy risk of anti-tumor necrosis factor alpha blockers: an overview of systematic reviews and meta-analyses.

Authors:  Yuehong Chen; Jianhong Sun; Yuan Yang; Yupeng Huang; Gang Liu
Journal:  Clin Rheumatol       Date:  2015-11-16       Impact factor: 2.980

7.  Malignancies and anti-TNF therapy in rheumatoid arthritis: a single-center observational cohort study.

Authors:  Nathalie Berghen; Laure-Anne Teuwen; Rene Westhovens; Patrick Verschueren
Journal:  Clin Rheumatol       Date:  2015-07-30       Impact factor: 2.980

8.  Tumor necrosis factor-alpha inhibitors and risk of non-Hodgkin lymphoma in a cohort of adults with rheumatologic conditions.

Authors:  Gregory S Calip; Pritesh R Patel; Sruthi Adimadhyam; Shan Xing; Zhaoju Wu; Karen Sweiss; Glen T Schumock; Todd A Lee; Brian C-H Chiu
Journal:  Int J Cancer       Date:  2018-04-16       Impact factor: 7.396

9.  Factors associated with fractures in HIV-infected persons: which factors matter?

Authors:  L Gedmintas; E A Wright; Y Dong; E Lehmann; J N Katz; D H Solomon; E Losina
Journal:  Osteoporos Int       Date:  2016-07-15       Impact factor: 4.507

10.  Do anti-TNF-α drugs increase cancer risk in rheumatoid arthritis patients?

Authors:  David A Clark
Journal:  Inflammopharmacology       Date:  2012-11-09       Impact factor: 4.473
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.